286 related articles for article (PubMed ID: 11222365)
21. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
[TBL] [Abstract][Full Text] [Related]
23. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
[TBL] [Abstract][Full Text] [Related]
24. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
[TBL] [Abstract][Full Text] [Related]
25. Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes.
Watanabe N; Kamachi Y; Koyama N; Hama A; Liang J; Nakamura Y; Yamamoto T; Isomura M; Kudo K; Kuzushima K; Kojima S
Cytotherapy; 2004; 6(5):514-22. PubMed ID: 15512918
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections.
Bao L; Cowan MJ; Dunham K; Horn B; McGuirk J; Gilman A; Lucas KG
J Immunother; 2012 Apr; 35(3):293-8. PubMed ID: 22421947
[TBL] [Abstract][Full Text] [Related]
27. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation.
Nakamura R; Cortez K; Solomon S; Battiwalla M; Gill VJ; Hensel N; Childs R; Barrett AJ
Bone Marrow Transplant; 2002 Aug; 30(4):235-42. PubMed ID: 12203140
[TBL] [Abstract][Full Text] [Related]
28. The potential association of CMV-specific CD8+ T lymphocyte reconstitution with the risk of CMV reactivation and persistency in post allogeneic stem cell transplant patients.
Shams El-Din AA; El-Desoukey NA; Amin Tawadrous DG; Fouad NMBE; Abdel-Mooti M; Hotar SF
Hematology; 2018 Sep; 23(8):463-469. PubMed ID: 29313439
[TBL] [Abstract][Full Text] [Related]
29. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.
Meijer E; Boland GJ; Verdonck LF
Clin Microbiol Rev; 2003 Oct; 16(4):647-57. PubMed ID: 14557291
[TBL] [Abstract][Full Text] [Related]
30. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation.
Tassi E; Noviello M; De Simone P; Lupo-Stanghellini MT; Doglio M; Serio F; Abbati D; Beretta V; Valtolina V; Oliveira G; Racca S; Campodonico E; Ruggiero E; Clerici D; Giglio F; Lorentino F; Dvir R; Xue E; Farina F; Oltolini C; Manfredi F; Vago L; Corti C; Bernardi M; Clementi M; Brix L; Ciceri F; Peccatori J; Greco R; Bonini C
Haematologica; 2023 Jun; 108(6):1530-1543. PubMed ID: 36200418
[TBL] [Abstract][Full Text] [Related]
33. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.
Borchers S; Bremm M; Lehrnbecher T; Dammann E; Pabst B; Wölk B; Esser R; Yildiz M; Eder M; Stadler M; Bader P; Martin H; Jarisch A; Schneider G; Klingebiel T; Ganser A; Weissinger EM; Koehl U
PLoS One; 2012; 7(12):e50248. PubMed ID: 23272059
[TBL] [Abstract][Full Text] [Related]
34. Possible Impact of Cytomegalovirus-Specific CD8
Ogonek J; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Borchers S; Koehl U; Weissinger EM; Hambach L
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1046-1053. PubMed ID: 28344058
[TBL] [Abstract][Full Text] [Related]
35. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
Abu-Khader A; Krause S
Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
37. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
38. [Cytomegalovirus-specific T cells immune reconstitution after human leukocyte antigen matched sibling donor allogeneic bone marrow plus peripheral blood hematopoietic stem cell transplantation].
Luo XH; Chang YJ; Huo MR; Li D; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):605-9. PubMed ID: 23134850
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
[TBL] [Abstract][Full Text] [Related]
40. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.
Blyth E; Clancy L; Simms R; Ma CK; Burgess J; Deo S; Byth K; Dubosq MC; Shaw PJ; Micklethwaite KP; Gottlieb DJ
Blood; 2013 May; 121(18):3745-58. PubMed ID: 23435462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
